Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — AusBiotech New York (June 2011)
7 slides from Neuren Pharmaceuticals's conference presentation, Jun 24, 2011
Slide 1: Developing innovative new medicines for acute and chronic neurological and psychiatric conditions
For personal use only Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com)
Slide 2: Neuren Pharmaceuticals
Neuren Pharmaceuticals For personal use only • Created to commercialize University of Auckland intellectual property • Focused on acute and chronic indications in neurology and psychiatry • Two molecules in Phase II clinical trials under US INDs • Trial costs covered by grants from US Army and NHMRC
Slide 3: Product Pipeline
Product Pipeline For personal use only Discovery Validated Lead Formulation Phase I Phase III Pre-Clinical Manufacturing Pre-Clinical Phase II Commercialization Efficacy Toxicology Motiva™ (nefiracetam) Apathy and depression (post-stroke, Parkinson’s, Alzheimer’s) NNZ-2566 (IV) Traumatic brain injur
Slide 4: Product overview: NNZ-2566
NNZ-2566 product overview For personal use only • IGF-1(1-3) is a naturally occurring neuroprotective peptide • NNZ-2566 is a synthetic analog of IGF-1(1-3) • Phase II for moderate to severe traumatic brain injury (Fast Track) • Direct costs covered by grants from US Army • 18 Level I and II trauma
Slide 5: Clinical profile
NNZ-2566 clinical profile For personal use only Mechanism of action Excitoxicity • NMDA Inflammation • Pro-inflammatory Neuronal Death • Necrosis activation cytokine elevation • Inhibits upregulation of inflammatory cytokines • Apoptosis • Ca influx • Free radical (IL-6, IL-1β, TNF-α, E-Selectin, IF
Slide 6: Commercialization strategy
NNZ-2566 commercialization strategy Market For personal use only • 1.5 million brain injuries per year in the US alone • No approved therapies • At $12,000 for IV and $3,000 for oral: • Moderate – severe = ~$2 billion • Mild = ~$2 billion Competitive advantages • Only product that addresses the full
Slide 7: Financials
Financials For personal use only • Market cap = US$13 million • Cash on hand = US$3.3 million • Burn rate = US$200k per month (net of clinical development costs covered by grants) • Shares on issue = 618 million • Share price = A$0.02 7 Larry Glass [lglass@neurenpharma.com; 301.758.2987]
Neuren Pharmaceuticals — AusBiotech New York (June 2011) on 6ix